After-Hours Earnings Report for May 12, 2025 : SPG, DVA, ACHR, BCO, ZI, POWI, RGTI, XENE, ACHC, HTZ, NFE, ARWR
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2025
0mins
Source: NASDAQ.COM
Earnings Reports Overview: Several companies, including Simon Property Group, DaVita, and Archer Aviation, are set to report their earnings for the quarter ending March 31, 2025, with most showing a decline in earnings per share compared to the previous year.
Price to Earnings Ratios: The Price to Earnings ratios for these companies vary, with some like Power Integrations showing significant increases in earnings forecasts, while others like New Fortress Energy and Xenon Pharmaceuticals report negative earnings projections.
Analyst Views on XENE
Wall Street analysts forecast XENE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XENE is 54.09 USD with a low forecast of 44.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 42.240
Low
44.00
Averages
54.09
High
62.00
Current: 42.240
Low
44.00
Averages
54.09
High
62.00
About XENE
Xenon Pharmaceuticals Inc. is a Canada-based neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing therapeutics to improve the lives of people living with neurological and psychiatric disorders. The Company is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The Company is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
